Telavancin versus Vancomycin for Hospital-Acquired Pneumonia due to Gram-positive Pathogens

The primary end point of the studies was met, indicating that telavancin is noninferior to vancomycin on the basis of clinical response in the treatment of HAP due to gram-positive pathogens.